CO-CHAIRS FOR 2020:
Cara Cassino, Chief Medical Officer, Contrafect
Michael Dawson, Director, Mike Dawson Antimicrobial Research Consultancy
As one of the most impactful pharmaceuticals for maintaining public health, antibiotics have been around since early 20th century and have since shown a need for significant progress in recent years. This is mainly due to its broad and indiscriminate use which has slowly given birth to multi- to extensively-drug resistant bacteria rendering our current last-resort antibiotic arsenal, including colistin, carbapenems, 3rd and 4th generation cephalosporins, useless.
This year’s event aims to showcase a suite of sessions focused on novel drugs and approaches, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR.
It is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020, along with leaders from the pharmaceutical industry, academia, regulatory and funding bodies, and public-private partnerships to discuss the way forward.
Category: Conferences | Science, Health and Medicine | Pharmaceuticals
Speakers: CO-CHAIR - Cara Cassino, Chief Medical Officer, Contrafect, CO-CHAIR - Michael Dawson, Director, Mike Dawson Antimicrobial Research Consultancy, Yuri Gleba, Professor, Founder, Nomad Bioscience, Samareh Lajaunias, Director, Combioxin SA, Cara Cassino, Chief Medical Officer, Contrafec, Mark Albrecht, Branch Chief, Antibacterials Program, BARDA/HHS, Stephen Barat, VP, Research and Early Development, Scynexis, Pedro Madureira, Co-Founder, CSO, Immunethep, Pedro Madureira, Co-Founder, CSO, Immunethep, Toni Perez, Chief Medical Officer, Senior Subject Matter Expert, Combioxin, Colm Leonard, Consultant Clinical Adviser/Consultant Thoracic Physician/Honorary Professor of Medicine, NICE and Machester University NHS Foundation Trust, Paul Finn, CEO, Oxford Drug Design, Martin Everett, CSO, Antabio, Francois Moreau, Scientific Director, Mutabilis, Daniel Walker, Professor of Bacteriology, University of Glasgow, Lorenzo Corsini, Co-Founder/CEO/R&D, Phagomed, David Roper, Professor of Biochemistry and Structural Biology, University of Warwick, Emma Leire, Microbiology Lead, Centauri Therapeutics, Peter Warn, Senior Vice President Anti-infective Discovery, Evotec (UK) Ltd, Antonio Felici, VP, Anti-Infectives, Evotec, Stephen Barat, VP, Preclinical Research and Early Development, Scynexis
Venue details: REMOTE ACCESS ONLY, London, United Kingdom